1Cheung AK, Sarnak MJ, Yan G, et al. (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 65, 2380–2389.
2Sarnak MJ, Levey AS, Schoolwerth AC, et al. (2003) Kidney disease as a risk factor for the development of cardiovascular disease. Circulation 108, 2154–2169.
3Go AS, Chertow GM & Fan D (2004) Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296–1305.
4Eikelboom JW, Lonn EM, Genest J, et al. (1999) Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131, 363–375.
5Bayes B, Pastor MC, Bonal J, et al. (2005) New cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int Suppl S39–S43.
6Wollesen F, Brattstrom B, Refsum H, et al. (1999) Plasma total homocysteine and cystein in relation to glomerular filtration rate. Kidney Int 55, 1028–1035.
7Mallamaci F, Zoccali C, Tripepi G, et al. (2002) Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61, 609–614.
8Buccianti G, Baragetti I, Bamonti F, et al. (2004) Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 17, 405–410.
9Lonn E, Yusuf S, Arnold MJ, et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567–1577.
10Bazzano LA, Reynolds K, Holder KN, et al. (2006) Effect of folic acid supplementation on the risk of cardiovascular diseases. JAMA 296, 2720–2726.
11Suliman ME, Lindholm B, Barany P, et al. (2007) Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial 20, 523–529.
12Zoungas S, McGrath BP, Branley P, et al. (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure – a multicenter, randomized, controlled trial. J Am Coll Cardiol 47, 1108–1116.
13Wrone EM, Homberger JM, Zehnder JL, et al. (2004) Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J Am Soc Nephrol 15, 420–426.
14Righetti M, Serbelloni P, Milani S, et al. (2006) Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24, 379–386.
15Qin X, Huo Y, Langman CB, et al. (2011) Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 6, 482–488.
16Righetti M, Ferrario GM, Milani S, et al. (2003) Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 9, PI19–PI24.
17Vianna AC, Mocelin AJ, Matsuo T, et al. (2007) Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11, 210–216.
18Nanayakkara PW, van Guldener C, ter Wee PM, et al. (2007) Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167, 1262–1270.
19Mann JFE, Sheridan P, McQueen MJ, et al. (2008) Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease – results of the renal Hope-2 study. Nephrol Dial Transplant 23, 645–653.
20Jamison RL, Hartigan P, Kaufman JS, et al. (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 1163–1170.
21House AA, Eliasziw M, Cattran DC, et al. (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603–1609.
22Heinz J, Kropf S, Domröse U, et al. (2010) B-vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease results of a randomized controlled trial. Circulation 121, 1432–1438.
23Widlansky ME, Gokce N, Keaney JF, et al. (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42, 1149–1160.
24Schachinger V, Britten MB & Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899–1906.
25Tatematsu S, Wakino S, Kanda T, et al. (2007) Role of nitric oxide producing and degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18, 741–749.
26van Guldener C, Janssen MJ, Lambert J, et al. (1998) Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 18, 282–289.
27van Guldener C, Janssen MJ, Lambert J, et al. (1998) No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in hemodialysis patients. Nephrol Dial Transplant 13, 106–112.
28Arnadottir M, Gudnason V & Hultberg B (2000) Treatment with different doses of folic acid in hemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 15, 524–528.
29Boushey CJ, Beresford SA, Omenn GS, et al. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049–1057.
30Tremblay R, Bonnardeaux A, Geadah D, et al. (2000) Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 58, 851–858.
31Billion S, Tribout B, Cadet E, et al. (2002) Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrol Dial Transplant 17, 455–461.
32Födinger M, Mannhalter C, Wölfl G, et al. (1997) Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52, 517–523.
33House AA, Wells GA, Donnelly JG, et al. (2000) Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 15, 1029–1034.
34Biasioli S, Schiavon R, Petrosino L, et al. (1998) Dialysis kinetics of homocysteine and reactive oxygen species. ASAIO J 44, M423–M432.
35Galli F, Benedetti S, Buoncristiani U, et al. (2003) The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 64, 748–755.
36Mudge DW, Rogers R, Hollett P, et al. (2005) Randomized trial of FX high flux vs. standard high flux dialysis for homocysteine clearance. Nephrol Dial Transplant 20, 2178–2185.
37Helal I, Smaoui W, Hamida FB, et al. (2010) Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl 21, 59–62.
38Mehrabi MR, Huber K, Serbecic N, et al. (2002) Enrichment of homocysteine in coronary arteries of patients with coronary artery disease. Thromb Res 107, 189–196.
39Jadad AR, Moore RA, Carroll D, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1–12.
40Ebbing M, Bønaa KH, Nygård O, et al. (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302, 2119–2126.